247 related articles for article (PubMed ID: 2563302)
1. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.
Ford JM; Prozialeck WC; Hait WN
Mol Pharmacol; 1989 Jan; 35(1):105-15. PubMed ID: 2563302
[TBL] [Abstract][Full Text] [Related]
2. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C.
Aftab DT; Ballas LM; Loomis CR; Hait WN
Mol Pharmacol; 1991 Nov; 40(5):798-805. PubMed ID: 1944244
[TBL] [Abstract][Full Text] [Related]
4. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
[TBL] [Abstract][Full Text] [Related]
5. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells.
Molnár J; Hevér A; Fakla I; Fischer J; Ocsovski I; Aszalós A
Anticancer Res; 1997; 17(1A):481-6. PubMed ID: 9066699
[TBL] [Abstract][Full Text] [Related]
7. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells.
Thimmaiah KN; Jayashree BS; Germain GS; Houghton PJ; Horton JK
Oncol Res; 1998; 10(1):29-41. PubMed ID: 9613455
[TBL] [Abstract][Full Text] [Related]
8. Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
Lee Y; Yeo H; Liu SH; Jiang Z; Savizky RM; Austin DJ; Cheng YC
J Med Chem; 2004 Oct; 47(22):5555-66. PubMed ID: 15481991
[TBL] [Abstract][Full Text] [Related]
9. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
10. The primary in vitro antitumor screening of "half-mustard type" phenothiazines.
Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Nacsa J; Molnár J
Anticancer Res; 1997; 17(5A):3409-23. PubMed ID: 9413180
[TBL] [Abstract][Full Text] [Related]
11. Neither lipophilicity nor membrane-perturbing potency of phenothiazine maleates correlate with the ability to inhibit P-glycoprotein transport activity.
Hendrich AB; Wesołowska O; Poła A; Motohashi N; Molnár J; Michalak K
Mol Membr Biol; 2003; 20(1):53-60. PubMed ID: 12745926
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
14. Intensely potent doxorubicin analogues: structure-activity relationship.
Farquhar D; Cherif A; Bakina E; Nelson JA
J Med Chem; 1998 Mar; 41(6):965-72. PubMed ID: 9526570
[TBL] [Abstract][Full Text] [Related]
15. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
16. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
Coley HM; Twentyman PR; Workman P
Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of P-glycoprotein transport function by N-acylphenothiazines.
Wesolowska O; Molnár J; Motohashi N; Michalak K
Anticancer Res; 2002; 22(5):2863-7. PubMed ID: 12530010
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
19. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
20. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance.
Hait WN; Aftab DT
Biochem Pharmacol; 1992 Jan; 43(1):103-7. PubMed ID: 1346493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
